Trade Graphite Bio, Inc. - GRPH CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Graphite Bio Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.26 |
Open* | 2.23 |
1-Year Change* | -35.36% |
Day's Range* | 2.21 - 2.25 |
52 wk Range | 1.59-3.64 |
Average Volume (10 days) | 203.93K |
Average Volume (3 months) | 2.69M |
Market Cap | 134.55M |
P/E Ratio | -100.00K |
Shares Outstanding | 58.00M |
Revenue | N/A |
EPS | -2.24 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 2.24 | 0.01 | 0.45% | 2.23 | 2.25 | 2.17 |
Nov 30, 2023 | 2.26 | 0.09 | 4.15% | 2.17 | 2.27 | 2.17 |
Nov 29, 2023 | 2.23 | 0.00 | 0.00% | 2.23 | 2.29 | 2.17 |
Nov 28, 2023 | 2.23 | -0.07 | -3.04% | 2.30 | 2.33 | 2.16 |
Nov 27, 2023 | 2.34 | 0.05 | 2.18% | 2.29 | 2.37 | 2.29 |
Nov 24, 2023 | 2.29 | 0.01 | 0.44% | 2.28 | 2.34 | 2.28 |
Nov 22, 2023 | 2.29 | 0.00 | 0.00% | 2.29 | 2.33 | 2.23 |
Nov 21, 2023 | 2.31 | 0.01 | 0.43% | 2.30 | 2.40 | 2.28 |
Nov 20, 2023 | 2.32 | 0.06 | 2.65% | 2.26 | 2.36 | 2.26 |
Nov 17, 2023 | 2.30 | 0.06 | 2.68% | 2.24 | 2.31 | 2.23 |
Nov 16, 2023 | 2.23 | 0.09 | 4.21% | 2.14 | 2.27 | 2.14 |
Nov 15, 2023 | 2.24 | 0.10 | 4.67% | 2.14 | 2.27 | 2.00 |
Nov 14, 2023 | 2.30 | 0.02 | 0.88% | 2.28 | 2.34 | 2.26 |
Nov 13, 2023 | 2.28 | 0.01 | 0.44% | 2.27 | 2.30 | 2.24 |
Nov 10, 2023 | 2.31 | 0.04 | 1.76% | 2.27 | 2.32 | 2.25 |
Nov 9, 2023 | 2.32 | 0.02 | 0.87% | 2.30 | 2.37 | 2.27 |
Nov 8, 2023 | 2.36 | 0.03 | 1.29% | 2.33 | 2.41 | 2.30 |
Nov 7, 2023 | 2.38 | 0.06 | 2.59% | 2.32 | 2.41 | 2.32 |
Nov 6, 2023 | 2.39 | 0.10 | 4.37% | 2.29 | 2.42 | 2.21 |
Nov 3, 2023 | 2.27 | -0.08 | -3.40% | 2.35 | 2.38 | 2.27 |
Graphite Bio, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 |
Total Operating Expense | 105.639 | 60.443 | 13.5 | 0.029 |
Selling/General/Admin. Expenses, Total | 32.852 | 22.511 | 4.377 | 0.029 |
Research & Development | 72.787 | 37.932 | 9.123 | 0 |
Operating Income | -105.639 | -60.443 | -13.5 | -0.029 |
Interest Income (Expense), Net Non-Operating | 0 | -0.04 | -0.08 | |
Other, Net | 4.587 | -10.317 | -54.833 | 0 |
Net Income Before Taxes | -101.052 | -70.76 | -68.373 | -0.109 |
Net Income After Taxes | -101.052 | -70.76 | -68.373 | -0.109 |
Net Income Before Extra. Items | -101.052 | -70.76 | -68.373 | -0.109 |
Net Income | -101.052 | -70.76 | -68.373 | -0.109 |
Income Available to Common Excl. Extra. Items | -101.052 | -70.76 | -68.373 | -0.109 |
Income Available to Common Incl. Extra. Items | -101.052 | -70.76 | -68.373 | -0.109 |
Diluted Net Income | -101.052 | -70.76 | -68.373 | -0.109 |
Diluted Weighted Average Shares | 54.8737 | 28.9193 | 58.079 | 58.079 |
Diluted EPS Excluding Extraordinary Items | -1.84154 | -2.44681 | -1.17724 | -0.00188 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Diluted Normalized EPS | -1.84154 | -2.44681 | -1.17724 | -0.00188 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 58.159 | 26.45 | 26.751 | 26.154 | 26.776 |
Selling/General/Admin. Expenses, Total | 7.455 | 7.623 | 8.289 | 7.852 | 8.999 |
Research & Development | 13.508 | 16.244 | 18.462 | 18.302 | 17.777 |
Operating Income | -58.159 | -26.45 | -26.751 | -26.154 | -26.776 |
Interest Income (Expense), Net Non-Operating | |||||
Other, Net | 2.845 | 2.587 | 2.152 | 1.472 | 0.84 |
Net Income Before Taxes | -55.314 | -23.934 | -24.599 | -24.682 | -25.936 |
Net Income After Taxes | -55.314 | -23.934 | -24.599 | -24.682 | -25.936 |
Net Income Before Extra. Items | -55.314 | -23.934 | -24.599 | -24.682 | -25.936 |
Net Income | -55.314 | -23.934 | -24.599 | -24.682 | -25.936 |
Income Available to Common Excl. Extra. Items | -55.314 | -23.934 | -24.599 | -24.682 | -25.936 |
Income Available to Common Incl. Extra. Items | -55.314 | -23.934 | -24.599 | -24.682 | -25.936 |
Diluted Net Income | -55.314 | -23.934 | -24.599 | -24.682 | -25.936 |
Diluted Weighted Average Shares | 56.7453 | 55.8645 | 55.7199 | 55.2061 | 54.5729 |
Diluted EPS Excluding Extraordinary Items | -0.97478 | -0.42843 | -0.44148 | -0.44709 | -0.47525 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.31929 | -0.38092 | -0.44148 | -0.44709 | -0.47525 |
Unusual Expense (Income) | 37.196 | 2.583 | |||
Gain (Loss) on Sale of Assets | 0 | -0.071 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total Current Assets | 275.365 | 381.736 | 21.103 | 0.006 |
Cash and Short Term Investments | 268.229 | 376.976 | 19.782 | 0.006 |
Cash & Equivalents | 47.73 | 376.976 | 19.782 | 0.006 |
Prepaid Expenses | 7.136 | 4.76 | 1.286 | 0 |
Other Current Assets, Total | 0 | 0.035 | 0 | |
Total Assets | 321.902 | 401.987 | 22.564 | 0.006 |
Property/Plant/Equipment, Total - Net | 28.21 | 18.081 | 1.461 | 0 |
Total Current Liabilities | 13.043 | 12.143 | 32.048 | 2.224 |
Accounts Payable | 2.608 | 2.453 | 0.63 | 0 |
Accrued Expenses | 10.435 | 9.69 | 2.356 | 0.019 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 2.205 |
Other Current Liabilities, Total | 0 | 29.062 | 0 | |
Total Liabilities | 25.611 | 17.937 | 32.364 | 2.224 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 12.568 | 5.794 | 0.316 | 0 |
Total Equity | 296.291 | 384.05 | -9.8 | -2.218 |
Redeemable Preferred Stock | 0 | 0 | 55.608 | 0 |
Common Stock | 0.001 | 0.001 | 0 | 0 |
Additional Paid-In Capital | 539.741 | 525.4 | 5.183 | 0 |
Retained Earnings (Accumulated Deficit) | -242.403 | -141.351 | -70.591 | -2.218 |
Total Liabilities & Shareholders’ Equity | 321.902 | 401.987 | 22.564 | 0.006 |
Total Common Shares Outstanding | 58.2218 | 58.0108 | 58.079 | 58.079 |
Property/Plant/Equipment, Total - Gross | 31.417 | 18.936 | 1.582 | |
Accumulated Depreciation, Total | -3.207 | -0.855 | -0.121 | |
Other Long Term Assets, Total | 3.005 | 2.17 | ||
Short Term Investments | 220.499 | |||
Long Term Investments | 15.322 | |||
Other Equity, Total | -1.048 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 238.783 | 251.171 | 270.307 | 275.365 | 298.492 |
Cash and Short Term Investments | 233.986 | 246.665 | 264.096 | 268.229 | 291.685 |
Cash & Equivalents | 182.988 | 128.506 | 69.811 | 47.73 | 56.391 |
Prepaid Expenses | 4.777 | 2.878 | 6.211 | 7.136 | 6.807 |
Other Current Assets, Total | 0.02 | 1.628 | |||
Total Assets | 266.228 | 287.044 | 309.996 | 321.902 | 334.845 |
Property/Plant/Equipment, Total - Net | 25.729 | 33.802 | 37.084 | 28.21 | 20.39 |
Property/Plant/Equipment, Total - Gross | 26.567 | 37.077 | 40.946 | 31.417 | 22.915 |
Accumulated Depreciation, Total | -0.838 | -3.275 | -3.862 | -3.207 | -2.525 |
Other Long Term Assets, Total | 1.716 | 2.071 | 2.605 | 3.005 | 2.56 |
Total Current Liabilities | 12.537 | 12.27 | 14.341 | 13.043 | 13.524 |
Accounts Payable | 3.753 | 2.72 | 1.992 | 2.608 | 3.972 |
Accrued Expenses | 8.784 | 9.55 | 12.349 | 10.435 | 9.552 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 62.209 | 62.898 | 33.772 | 25.611 | 18.392 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 49.672 | 50.628 | 19.431 | 12.568 | 4.868 |
Total Equity | 204.019 | 224.146 | 276.224 | 296.291 | 316.453 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 548.249 | 546.067 | 543.029 | 539.741 | 535.852 |
Retained Earnings (Accumulated Deficit) | -344.136 | -321.651 | -266.337 | -242.403 | -217.804 |
Total Liabilities & Shareholders’ Equity | 266.228 | 287.044 | 309.996 | 321.902 | 334.845 |
Total Common Shares Outstanding | 57.9719 | 57.9893 | 58.1948 | 58.2218 | 58.1493 |
Short Term Investments | 50.998 | 118.159 | 194.285 | 220.499 | 235.294 |
Long Term Investments | 0 | 0 | 0 | 15.322 | 13.403 |
Other Equity, Total | -0.095 | -0.271 | -0.469 | -1.048 | -1.596 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Net income/Starting Line | -101.052 | -70.76 | -68.373 | -0.109 |
Cash From Operating Activities | -87.98 | -52.852 | -8.721 | -0.019 |
Cash From Operating Activities | 2.352 | 0.734 | 0.121 | 0 |
Non-Cash Items | 17.928 | 19.672 | 57.822 | 0.08 |
Changes in Working Capital | -7.208 | -2.498 | 1.709 | 0.01 |
Cash From Investing Activities | -241.863 | -5.74 | -1.545 | 0 |
Capital Expenditures | -6.594 | -5.74 | -1.545 | 0 |
Cash From Financing Activities | 0.597 | 417.467 | 30.077 | 0 |
Issuance (Retirement) of Stock, Net | 0.676 | 417.467 | 25.077 | 0 |
Issuance (Retirement) of Debt, Net | 0 | 5 | 0 | |
Net Change in Cash | -329.246 | 358.875 | 19.811 | -0.019 |
Other Investing Cash Flow Items, Total | -235.269 | |||
Financing Cash Flow Items | -0.079 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -23.934 | -101.052 | -76.453 | -51.771 | -25.835 |
Cash From Operating Activities | -21.074 | -87.98 | -65.551 | -43.334 | -21.24 |
Cash From Operating Activities | 0.654 | 2.352 | 1.67 | 1.018 | 0.44 |
Non-Cash Items | 3.267 | 17.928 | 13.887 | 9.723 | 4.839 |
Changes in Working Capital | -1.061 | -7.208 | -4.655 | -2.304 | -0.684 |
Cash From Investing Activities | 43.163 | -241.863 | -255.387 | -258.883 | -170.666 |
Capital Expenditures | -0.383 | -6.594 | -5.573 | -4.658 | -3.273 |
Cash From Financing Activities | -0.008 | 0.597 | 0.353 | 0.412 | 0 |
Financing Cash Flow Items | -0.008 | -0.079 | -0.079 | -0.015 | 0 |
Issuance (Retirement) of Stock, Net | 0.676 | 0.432 | 0.427 | 0 | |
Net Change in Cash | 22.081 | -329.246 | -320.585 | -301.805 | -191.906 |
Issuance (Retirement) of Debt, Net | |||||
Other Investing Cash Flow Items, Total | 43.546 | -235.269 | -249.814 | -254.225 | -167.393 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Versant Ventures | Venture Capital | 28.3133 | 16416117 | 0 | 2023-03-31 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 14.7265 | 8538446 | 0 | 2023-06-30 | LOW |
Samsara BioCapital, LLC | Venture Capital | 14.59 | 8459314 | 0 | 2023-06-30 | LOW |
Porteus (Matthew) | Individual Investor | 6.0857 | 3528529 | 0 | 2023-03-31 | LOW |
Tang Capital Management, LLC | Hedge Fund | 3.5971 | 2085625 | 57159 | 2023-06-30 | MED |
Prosight Capital | Hedge Fund | 2.932 | 1700000 | 823334 | 2023-06-30 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6468 | 1534623 | 1064173 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.3795 | 1379642 | 145204 | 2023-06-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 2.0771 | 1204295 | 33118 | 2023-06-30 | LOW |
Lehrer-Graiwer (Joshua) | Individual Investor | 2.0036 | 1161670 | 0 | 2023-03-31 | LOW |
Stanford Management Company | Endowment Fund | 1.2126 | 703071 | 0 | 2023-06-30 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8937 | 518170 | 270790 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.7605 | 440967 | 351816 | 2023-06-30 | LOW |
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 0.7008 | 406308 | 0 | 2023-06-30 | LOW |
OUP Management Co., LLC | Venture Capital | 0.7008 | 406308 | 0 | 2023-06-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.5643 | 327204 | -25292 | 2023-06-30 | HIGH |
Gutry (Phil) | Individual Investor | 0.5577 | 323355 | 24884 | 2023-03-31 | LOW |
Privium Fund Management (UK) Ltd | Investment Advisor | 0.4534 | 262858 | -18903 | 2023-06-30 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 0.421 | 244100 | 15900 | 2023-06-30 | HIGH |
Bellecapital Partners AG | Investment Advisor/Hedge Fund | 0.4104 | 237944 | 0 | 2023-02-28 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Graphite Bio, Inc. Company profile
About Graphite Bio Inc
Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. The Company's pipeline includes multiple programs including its gene replacement program, GPH201 for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene prevent normal immune system function, and targeted gene insertion program, GPH301 for Gaucher disease, and multiple additional programs in both HSCs and other cell types.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Graphite Bio Inc revenues was not reported. Net loss increased 3% to $70.8M. Higher net loss reflects Research and development - Balancing val increase from $9M to $35.2M (expense), General and administrative - Balancing v increase from $4.3M to $17.3M (expense), Stock-based Compensation in SGA increase from $54K to $5.2M (expense).
Industry: | Bio Therapeutic Drugs |
611 Gateway Blvd, Suite 120
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com